PMV Pharmaceuticals has completed enrollment of the platinum-resistant or refractory ovarian cancer patients required for the primary analysis of its registrational Phase 2 PYNNACLE trial, bringing the first-in-class p53 reactivator rezatapopt closer to a potential United States regulatory filing. The company continues to target the first quarter of 2027 for a New Drug Application seeking accelerated approval in patients whose tumors carry the TP53 Y220C mutation. Rezatapopt is being administered as a 2,000-milligram once-daily oral monotherapy, and earlier Phase 2 findings have already produced confirmed responses in a heavily treated ovarian cancer population. The completion of primary-analysis enrollment now shifts attention from recruitment toward whether the mature dataset can reproduce an overall response rate strong and durable enough to support the planned application.
The development strategy is unusual because PMV Pharmaceuticals is attempting to pharmacologically restore the function of a mutated tumor-suppressor protein rather than block a conventional oncogenic target. Rezatapopt selectively binds a structural pocket created by the Y220C mutation in p53 and is designed to stabilize the protein in a configuration resembling normal p53, potentially restoring its ability to suppress tumor growth. Phase 1 results involving 77 heavily pretreated patients provided clinical proof of concept across several solid tumors, while the registrational Phase 2 program has increasingly concentrated the near-term regulatory opportunity on ovarian cancer.
Earlier PYNNACLE results set a demanding benchmark for the completed ovarian cancer cohort
Updated findings presented during the 2026 Society of Gynecologic Oncology Annual Meeting showed a confirmed overall response rate of 44% among 72 evaluable patients with platinum-resistant or refractory ovarian cancer harboring TP53 Y220C. Thirty-two patients achieved confirmed responses, consisting of one complete response and 31 partial responses. Median time to response was 1.3 months and median duration of response reached 8.2 months. Two additional patients subsequently developed unconfirmed partial responses, raising the preliminary response proportion to 46% among 74 patients at that later point.
Those figures provide a meaningful foundation for the accelerated approval strategy, but the completed primary analysis will need to confirm them under the trial’s prespecified assessment framework. PYNNACLE is a single-arm study, so it does not directly compare rezatapopt with another therapy. For an accelerated approval application built around tumor response, the magnitude, durability and independent confirmation of responses become particularly important because there is no randomized control arm demonstrating an improvement over existing treatment.
The trial’s broader Phase 2 portion is structured as a registrational expansion study across ovarian, lung, breast, endometrial and other solid tumors. Patients must have tumors carrying the TP53 Y220C mutation, while the clinical activity reported so far has been concentrated in patients whose cancers are also KRAS wild-type. The study is being conducted across approximately 70 sites, giving PMV Pharmaceuticals experience with identifying and enrolling a molecularly defined population that represents only a subset of patients with otherwise common cancers.
That molecular selection is central to rezatapopt’s potential. TP53 alterations overall are extraordinarily common across cancer, but rezatapopt is not intended to reactivate every mutant form of p53. It is designed specifically around the Y220C structural alteration, meaning tumor genomic testing would be necessary to identify eligible patients if the treatment reaches the market.
Rezatapopt aims to turn a historically difficult cancer target into a precision medicine
The p53 protein normally acts as one of the body’s major defenses against cancer by responding to cellular damage and helping prevent abnormal cells from continuing to divide. Mutations in TP53 can disable that tumor-suppressive function, allowing malignant cells to survive and proliferate. PMV Pharmaceuticals says TP53 mutations occur in approximately half of cancers, making p53 one of oncology’s most important but historically difficult therapeutic targets.
The Y220C mutation creates a pocket in the destabilized p53 protein that rezatapopt is designed to occupy. By binding that pocket, the small molecule is intended to restore the normal structural shape and tumor-suppressor activity of p53. Biomarker evidence and clinical responses from the Phase 1 program were consistent with this selective mechanism, while responding patients in the first-in-human study carried TP53 Y220C tumors and were KRAS wild-type.
The Phase 1 experience also provided the safety foundation for the 2,000-milligram recommended Phase 2 dose. Seventy-seven heavily pretreated patients received rezatapopt across dose-escalation cohorts, with PMV Pharmaceuticals reporting that the medicine was generally well tolerated and that dose-limiting toxicities were infrequent. Objective responses were observed across multiple tumor types, establishing the clinical proof of concept that mutant p53 reactivation could translate into measurable tumor shrinkage in humans.
The challenge now is much narrower and more consequential. Demonstrating biological activity across several tumors establishes the platform idea, but obtaining accelerated approval requires a sufficiently persuasive result in a defined indication. Platinum-resistant or refractory ovarian cancer has become PMV Pharmaceuticals’ first regulatory target because the response signal there has been among the strongest observed in PYNNACLE.
Accelerated approval could move rezatapopt toward the market without a conventional Phase 3 first
PMV Pharmaceuticals continues to plan an NDA submission during the first quarter of 2027 for platinum-resistant or refractory ovarian cancer with TP53 Y220C. The company has described the Phase 2 monotherapy study as registrational and is pursuing accelerated approval, a pathway that can permit earlier authorization based on an endpoint considered reasonably likely to predict clinical benefit while additional confirmatory evidence is generated.
Rezatapopt already holds FDA Fast Track designation for locally advanced or metastatic solid tumors containing the p53 Y220C mutation. The regulator has also granted Orphan Drug designation for TP53 Y220C-positive ovarian, fallopian tube and primary peritoneal cancers. If an orphan-designated drug ultimately satisfies the relevant requirements for approval, the designation can provide regulatory incentives that may include seven years of United States orphan-drug exclusivity for the approved indication.
A planned submission does not mean the existing dataset is guaranteed to be accepted as sufficient. The FDA can request additional analyses, manufacturing information or clinical evidence, while accelerated approval would generally leave a continuing obligation to verify clinical benefit. The primary-analysis dataset will therefore need to support not simply an attractive response percentage, but confidence that those responses are real, durable and clinically meaningful in the intended population.
The enrollment milestone nevertheless materially reduces execution uncertainty. Recruiting a genetically selected group of patients with advanced ovarian cancer across a global trial network can be challenging, and PMV Pharmaceuticals has now secured the population required to generate the central analysis on which its near-term regulatory strategy depends.
PMV’s cash exceeds its market value as investors wait for the registrational dataset
PMV Pharmaceuticals ended June with $79.4 million in cash, cash equivalents and marketable securities, down from $112.9 million at the end of 2025. The company expects that funding to support operations through the second quarter of 2027, which would carry it beyond the currently targeted first-quarter NDA submission. Research and development expenses declined to $14.7 million during the second quarter from $18.4 million a year earlier, while the quarterly net loss narrowed to $18.1 million from $21.2 million.
PMV Pharmaceuticals shares were trading near $1.24 late Friday morning on August 14, up about 2.1% from the previous close, with a market capitalization of approximately $66 million. The company’s reported $79.4 million cash and investment balance therefore exceeds its current equity market capitalization, illustrating the degree of skepticism investors continue to place on rezatapopt’s regulatory and commercial prospects despite the encouraging response data. The comparison does not establish that the shares are undervalued because PMV Pharmaceuticals continues to consume cash and rezatapopt remains an unapproved, single-asset-driven clinical program.
The modest positive move on August 14 suggests the enrollment milestone is supportive without substantially changing investor expectations ahead of the mature PYNNACLE analysis. That interpretation is an inference from market behavior rather than a confirmed explanation from shareholders. The much larger valuation event is likely to be the quality of the completed primary dataset and whether it keeps the first-quarter 2027 accelerated approval filing on schedule.
Rezatapopt has already provided one of the clearest clinical demonstrations that a small molecule can reactivate a structurally altered p53 protein in human cancer. Completing enrollment brings PMV Pharmaceuticals closer to determining whether that scientific achievement can become an approved precision oncology medicine. The next dataset must show that the 44% confirmed response rate and eight-month-plus response durability previously observed in ovarian cancer remain intact when the registrational analysis is finalized.
